Venus Medtech (Hangzhou) Inc. (HKG:2500)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.410
+0.110 (4.78%)
Mar 10, 2026, 3:59 PM HKT
Market Cap 1.01B
Revenue (ttm) 468.17M
Net Income (ttm) -704.14M
Shares Out 437.90M
EPS (ttm) -1.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,715,500
Average Volume 1,186,475
Open 2.350
Previous Close 2.300
Day's Range 2.280 - 2.440
52-Week Range 1.590 - 5.470
Beta 1.11
RSI 32.14
Earnings Date Mar 27, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Ve... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2009
Employees 605
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2500
Full Company Profile

Financial Performance

In 2024, Venus Medtech (Hangzhou)'s revenue was 470.83 million, a decrease of -4.18% compared to the previous year's 491.37 million. Losses were -714.31 million, 1.50% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.